Have a feature idea you'd love to see implemented?
Let us know!
LPCN Lipocine Inc
Price (delayed)
$5.5
Market cap
$29.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.59
Enterprise value
$23.86M
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN
Highlights
Lipocine's EPS has increased by 31% YoY and by 6% QoQ
LPCN's net income is up by 30% YoY and by 5% QoQ
Lipocine's equity has decreased by 26% YoY and by 11% QoQ
The quick ratio has decreased by 25% from the previous quarter and by 12% YoY
Key stats
What are the main financial stats of LPCN
Market
Valuations
Earnings
Shares outstanding
5.35M
Market cap
$29.41M
Enterprise value
$23.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.39
Price to sales (P/S)
6.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.97
Revenue
$4.8M
EBIT
-$8.49M
EBITDA
-$8.45M
Free cash flow
-$4.73M
Per share
Balance sheet
Liquidity
EPS
-$1.59
Free cash flow per share
-$0.88
Book value per share
$3.97
Revenue per share
$0.9
TBVPS
$4.31
Total assets
$23.03M
Total liabilities
$1.82M
Debt
$0
Equity
$21.21M
Working capital
$21.09M
Debt to equity
0
Current ratio
12.56
Quick ratio
12.36
Net debt/EBITDA
0.66
Margins
Efficiency
Dividend
EBITDA margin
-176.1%
Gross margin
100%
Net margin
-176.8%
Operating margin
-202.2%
Return on assets
-35.3%
Return on equity
-38.6%
Return on invested capital
-48.1%
Return on capital employed
-40%
Return on sales
-176.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LPCN stock price
How has the Lipocine stock price performed over time
Intraday
-1.08%
1 week
8.27%
1 month
13.64%
1 year
114.84%
YTD
97.13%
QTD
22.49%
Financial performance
How have Lipocine's revenue and profit performed over time
Revenue
$4.8M
Gross profit
$4.8M
Operating income
-$9.71M
Net income
-$8.49M
Gross margin
100%
Net margin
-176.8%
LPCN's net margin has surged by 99% year-on-year and by 7% since the previous quarter
LPCN's operating margin has surged by 99% year-on-year and by 8% since the previous quarter
LPCN's net income is up by 30% YoY and by 5% QoQ
The company's operating income rose by 29% YoY and by 6% QoQ
Growth
What is Lipocine's growth rate over time
Valuation
What is Lipocine stock price valuation
P/E
N/A
P/B
1.39
P/S
6.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.97
Lipocine's EPS has increased by 31% YoY and by 6% QoQ
The P/B is 42% less than the 5-year quarterly average of 2.4 but 16% more than the last 4 quarters average of 1.2
Lipocine's equity has decreased by 26% YoY and by 11% QoQ
Efficiency
How efficient is Lipocine business performance
Lipocine's return on sales has surged by 99% YoY and by 7% QoQ
The ROIC has contracted by 19% YoY and by 5% from the previous quarter
Lipocine's ROE has decreased by 7% YoY and by 2.7% from the previous quarter
LPCN's ROA is down by 3.5% year-on-year and by 2% since the previous quarter
Dividends
What is LPCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LPCN.
Financial health
How did Lipocine financials performed over time
The current ratio has contracted by 26% from the previous quarter and by 15% YoY
The quick ratio has decreased by 25% from the previous quarter and by 12% YoY
LPCN's debt is 100% smaller than its equity
Lipocine's equity has decreased by 26% YoY and by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.